The Anti-SARS-CoV-2 S-Protein IgG, Which Is Detected Using the Chemiluminescence Microparticle Immunoassay (CMIA) in Individuals Having Either a History of COVID-19 Vaccination and/or SARS-CoV-2 Infection, Showed a High-Titer Neutralizing Effect

被引:1
|
作者
Cin, Dilan [1 ,2 ]
Soguksu, Pinar [1 ]
Oren, Meryem Merve [3 ]
Ozgulnar, Nuray [3 ]
Agacfidan, Ali [1 ]
Mese, Sevim [1 ]
机构
[1] Istanbul Univ, Istanbul Med Fac, Dept Med Microbiol, TR-34093 Istanbul, Turkiye
[2] Istanbul Univ, Inst Hlth Sci, TR-34126 Istanbul, Turkiye
[3] Istanbul Univ, Istanbul Med Fac, Dept Publ Hlth, TR-34093 Istanbul, Turkiye
来源
VIRUSES-BASEL | 2024年 / 16卷 / 09期
关键词
SARS-CoV-2; IgG; surrogate virus neutralization test (sVNT); chemiluminescent microparticle immunoassay (CMIA);
D O I
10.3390/v16091409
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Neutralizing antibodies plays a primary role in protective immunity by preventing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from entering the cells. Therefore, characterization of antiviral immunity is important for protection against SARS-CoV-2. In this study, the neutralizing effect of the anti-SARS-CoV-2 S1 protein IgG, which was detected using the chemiluminescence microparticle immunoassay (CMIA)-based SARS-CoV-2 IgG II Quant (Abbott, Waukegan, IL, USA) test in SARS-CoV-2 infected and/or vaccinated individuals, was investigated with a surrogate virus neutralization test (sVNT). In total, 120 Seropositive individuals were included in this study. They were divided into two groups: Vaccinated (n = 60) and Vaccinated + Previously Infected (n = 60). A commercial sVNT, the ACE2-RBD Neutralization Test (Dia.Pro, Milan, Italy), was used to assess the neutralizing effect. The assay is performed in two steps: screening and titration. The screening showed positive results in all seropositive samples. Low titration in 1.7%, medium titration in 5%, and high titration in 93.3% of the Vaccinated group, and medium titration in 1.7% and high titration in 98.3% of the other group, as obtained from the ACE2-RBD titration test. A strong positive and significant correlation was found between the SARS-CoV-2 IgG II Quant test and the ACE2-RBD titration test at the 1/32 titration level for both groups (p < 0.001 for both). This study shows that the SARS-CoV-2 IgG detected using the CMIA method after SARS-CoV-2 infection and/or vaccination has a high neutralizing titration by using the sVNT. In line with these data, knowledge that seropositivity determined by CMIA also indicates a strong neutralizing effect contributes to countrywide planning for protecting the population.
引用
收藏
页数:13
相关论文
共 34 条
  • [21] Novel B-Cell Epitopes of Non-Neutralizing Antibodies in the Receptor-Binding Domain of the SARS-CoV-2 S-Protein with Different Effects on the Severity of COVID-19
    Matveev, Andrey L.
    Pyankov, Oleg V.
    Khlusevich, Yana A.
    Tyazhelkova, Olga V.
    Emelyanova, Ljudmila A.
    Timofeeva, Anna M.
    Shipovalov, Andrey V.
    Chechushkov, Anton V.
    Zaitseva, Natalia S.
    Kudrov, Gleb A.
    Yusubalieva, Gaukhar M.
    Yussubaliyeva, Saule M.
    Zhukova, Oxana A.
    Tikunov, Artem Yu.
    Baklaushev, Vladimir P.
    Sedykh, Sergey E.
    Lifshits, Galina I.
    Tikunova, Nina V.
    BIOCHEMISTRY-MOSCOW, 2023, 88 (09) : 1205 - 1214
  • [22] Novel B-Cell Epitopes of Non-Neutralizing Antibodies in the Receptor-Binding Domain of the SARS-CoV-2 S-Protein with Different Effects on the Severity of COVID-19
    Andrey L. Matveev
    Oleg V. Pyankov
    Yana A. Khlusevich
    Olga V. Tyazhelkova
    Ljudmila A. Emelyanova
    Anna M. Timofeeva
    Andrey V. Shipovalov
    Anton V. Chechushkov
    Natalia S. Zaitseva
    Gleb A. Kudrov
    Gaukhar M. Yusubalieva
    Saule M. Yussubaliyeva
    Oxana A. Zhukova
    Artem Yu. Tikunov
    Vladimir P. Baklaushev
    Sergey E. Sedykh
    Galina I. Lifshits
    Nina V. Tikunova
    Biochemistry (Moscow), 2023, 88 : 1205 - 1214
  • [23] Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG
    Salazar, Eric
    Christensen, Paul A.
    Graviss, Edward A.
    Nguyen, Duc T.
    Castillo, Brian
    Chen, Jian
    Lopez, Bevin, V
    Eagar, Todd N.
    Yi, Xin
    Zhao, Picheng
    Rogers, John
    Shehabeldin, Ahmed
    Joseph, David
    Masud, Faisal
    Leveque, Christopher
    Olsen, Randall J.
    Bernard, David W.
    Gollihar, Jimmy
    Musser, James M.
    AMERICAN JOURNAL OF PATHOLOGY, 2021, 191 (01): : 90 - 107
  • [24] Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay
    Salvagno, Gian Luca
    Henry, Brandon M.
    Pighi, Laura
    De Nitto, Simone
    Gianfilippi, Gian Luca
    Lippi, Giuseppe
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2021, 59 (10) : E377 - E379
  • [25] Autoinflammatory Diseases and COVID-19 Vaccination: Analysis of SARS-CoV-2 Anti-S-RBD IgG Levels in a Cohort of Patients Receiving IL-1 Inhibitors
    Bindoli, Sara
    Baggio, Chiara
    Galozzi, Paola
    Vesentini, Filippo
    Doria, Andrea
    Cosma, Chiara
    Padoan, Andrea
    Sfriso, Paolo
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (14)
  • [26] Clinical performance of the Elecsys® anti-SARS-CoV-2 combined in an algorithm with two specific anti-IgG immunoassays for the evaluation of the serological response of patients with COVID-19 in a population with a high prevalence of infection
    Gabaldo-Barrios, Xavier
    Iftimie, Simona
    Hernandez-Aguilera, Anna
    Pujol, Isabel
    Ballester, Frederic
    Fernandez, Luis
    Cladellas, Sara
    Castro, Antoni
    Joven, Jorge
    Camps, Jordi
    Simo, Josep M.
    ANNALS OF CLINICAL BIOCHEMISTRY, 2021, 58 (06) : 614 - 621
  • [27] Anti-SARS-CoV-2 IgG antibody titer after BNT162b2 mRNA COVID-19 vaccination in Japanese patients who underwent renal replacement therapy, hemodialysis, peritoneal dialysis, and kidney transplantation
    Iwabuchi, Ryohei
    Harada, Makoto
    Yamada, Aiko
    Aomura, Daiki
    Yamada, Yosuke
    Sonoda, Kosuke
    Nakazawa, Hideyuki
    Sakai, Kaoko
    Mizukami, Etsuko
    Hashimoto, Koji
    Kamijo, Yuji
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2023, 27 (08) : 660 - 671
  • [28] Anti-SARS-CoV-2 IgG antibody titer after BNT162b2 mRNA COVID-19 vaccination in Japanese patients who underwent renal replacement therapy, hemodialysis, peritoneal dialysis, and kidney transplantation
    Ryohei Iwabuchi
    Makoto Harada
    Aiko Yamada
    Daiki Aomura
    Yosuke Yamada
    Kosuke Sonoda
    Hideyuki Nakazawa
    Kaoko Sakai
    Etsuko Mizukami
    Koji Hashimoto
    Yuji Kamijo
    Clinical and Experimental Nephrology, 2023, 27 : 660 - 671
  • [29] Prolonged SARS-CoV-2 Infection in Patients Receiving Anti-CD20 Monoclonal Antibodies: A Diagnostic Challenged by Negative Nasopharyngeal RT-PCR and Successful Treatment with COVID-19 High-Titer Convalescent Plasma
    Da Silva, Lea
    Klopfenstein, Timothee
    Gendrin, Vincent
    Clouet, Julien
    Toko, Lynda
    Richier, Quentin
    Leriche, Thomas
    Nicolas, Raoul
    Queijo, Alexis
    Sreiri, Nour
    Lacombe, Karine
    Zayet, Souheil
    VIRUSES-BASEL, 2023, 15 (11):
  • [30] Correlation of Anti-SARS-CoV-2 S1-specific IgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers
    Izak, Marina
    Stoyanov, Evgeniy
    Dezuraev, Keren
    Shinar, Eilat
    VACCINE, 2022, 40 (03) : 428 - 431